Corcept Therapeutics Incorporated (CORT)

NASDAQ: CORT · IEX Real-Time Price · USD
23.51
-0.31 (-1.30%)
Apr 12, 2024, 4:00 PM EDT - Market closed
-1.30%
Market Cap 2.43B
Revenue (ttm) 482.38M
Net Income (ttm) 105.50M
Shares Out 103.52M
EPS (ttm) 0.94
PE Ratio 25.01
Forward PE 20.92
Dividend n/a
Ex-Dividend Date n/a
Volume 401,678
Open 23.66
Previous Close 23.82
Day's Range 23.31 - 23.82
52-Week Range 20.87 - 34.28
Beta 0.48
Analysts Strong Buy
Price Target 33.60 (+42.92%)
Earnings Date May 1, 2024

About CORT

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 352
Stock Exchange NASDAQ
Ticker Symbol CORT
Full Company Profile

Financial Performance

In 2023, CORT's revenue was $482.38 million, an increase of 20.04% compared to the previous year's $401.86 million. Earnings were $105.50 million, an increase of 4.15%.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CORT stock is "Strong Buy." The 12-month stock price forecast is $33.6, which is an increase of 42.92% from the latest price.

Price Target
$33.6
(42.92% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat sev...

13 days ago - GlobeNewsWire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...

2 months ago - GlobeNewsWire

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...

2 months ago - GlobeNewsWire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a ...

2 months ago - GlobeNewsWire

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: KTRAMISTMOTSRPID
3 months ago - Benzinga

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...

5 months ago - GlobeNewsWire

Corcept Appoints Monica Tellado as President, Emerging Markets

MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...

5 months ago - GlobeNewsWire

Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)

MENLO PARK, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...

6 months ago - GlobeNewsWire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on ...

6 months ago - GlobeNewsWire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

MENLO PARK, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...

9 months ago - GlobeNewsWire

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on...

9 months ago - GlobeNewsWire

Corcept's Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)

MENLO PARK, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...

9 months ago - GlobeNewsWire

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat sever...

1 year ago - GlobeNewsWire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on...

1 year ago - GlobeNewsWire

Corcept Therapeutics Announces Final Results of Tender Offer

MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat sev...

1 year ago - GlobeNewsWire

Corcept Therapeutics Initiates CATALYST Clinical Trial

MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat sev...

1 year ago - GlobeNewsWire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update

MENLO PARK, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...

1 year ago - GlobeNewsWire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a ...

1 year ago - GlobeNewsWire

Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation

MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...

1 year ago - GlobeNewsWire

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT

New York, New York--(Newsfile Corp. - January 1, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of...

1 year ago - Newsfile Corp

NATIONALLY RANKED ROSEN LAW FIRM Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT

NEW YORK , Dec. 30, 2022 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Corcept Therape...

1 year ago - PRNewsWire

EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Corcept Therapeutics Incorpo...

1 year ago - Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporate...

1 year ago - Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporate...

1 year ago - Business Wire

5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More - Corcept Therapeutics (NASDAQ:CORT), Cytek Biosciences (NASDAQ:CTKB)

The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies.

Other symbols: CTKB
1 year ago - Benzinga